Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

A.G. Dinmohamed, Y. van Norden, O. Visser, E.F.M. Posthuma, P.C. Huijgens, P. Sonneveld, A.A. van de Loosdrecht, M. Jongen-Lavrencic

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2449-2451
JournalLeukemia
Volume29
Issue number12
DOIs
Publication statusPublished - 2015

Cite this